Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL

Tissue Antigens

Volumn 61, Issue 2, 2003, Pages 136-145

  Koga, M ^a,b   Shichijo, Shigeki ^a   Yamada, A ^a,b   Ashihara, J ^a,b   Sawamizu, H ^a   Kusukawa, J ^a   Itoh, K ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

Cancer; CTL; HLA A26; Immunotherapy; Peptide vaccine

Indexed keywords

HLA A2 ANTIGEN; HLA A26 ANTIGEN; PROTEIN L10A; PROTEIN S II; RIBOSOME PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALLELE; ANTIGEN RECOGNITION; ARTICLE; CANCER; CANCER CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MONOCYTE; MUSCLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TESTIS;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CELL LINE; CELL LINE, TUMOR; DNA, COMPLEMENTARY; EPITOPES; FEMALE; GENE EXPRESSION; HLA-A ANTIGENS; HUMANS; MALE; PREGNANCY; RIBOSOMAL PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TISSUE DISTRIBUTION;

EID: 0038556963     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0001-2815.2002.00009.x     Document Type: Article

References (31)

1. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Sci U S A 1994: 91: 3515-9.
2. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995: 181: 2109-17.
3. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neuderived peptide. Proc Natl Acad Sci USA 1995: 92: 432-6.
4. Gomi S, Nakao M, Niiya F et al. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999: 163: 4994-5004.
5. Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001: 61: 6459-66.
6. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994: 12: 337-65.
7. Imanishi T, Akaza T, Kimura A, et al. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Proceedings of the 11th International Histocompatibility Workshop and Conference. Tsuji K, Aizawa M, T Sasazuki T, eds. Oxford, UK: Oxford Scientific publications, 1992: 1065-220.
8. Shichijo S, Nakao M, Imai Y et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998: 187: 277-88.
9. Inoue Y, Nakao M, Matsunaga K et al. Induction of human leukocyte antigen A26-restricted and tumor-specific cytotoxic T lymphocytes by a single peptide of the SART1 antigen in patients with cancer with different A26 subtypes. J Immunother 2000: 23: 296-303.
10. Miyagi Y, Imai N, Sasatomi T et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001: 7: 3950-62.
11. Lee P, Wang F, Kuniyoshi J et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001: 19: 3836-47.
12. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998: 4: 32832.
13. Nakao M, Yamana H, Imai Y et al. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 1995: 55: 4248-52.
14. Yamada N, Ishikawa Y, Dumrese T et al. Role of anchor residues in peptide binding to three HLA-A26 molecules. Tissue Antigens 1999: 54: 325-32.
15. Dumrese T, Stevanovi'c S, Seeger FH et al. HLA-A26 subtype A pockets accommodate acidic N-termini of ligands. Immunogenetics 1998: 48: 350-3.
16. Suzuki N, Maeda Y, Tanaka S et al. Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer 2002: 98: 45-50.
17. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002: 32: 826-36.
18. Chen FW, Ioannou YA. Ribosomal proteins in cell proliferation and apoptosis. Int Rev Immunol 1999: 18: 429-48.
19. Barnard GF, Staniunas RJ, Mori M et al. Gastric and hepatocellular carcinomas do not overexpress the same ribosomal protein messenger RNAs as colonic carcinoma. Cancer Res 1993: 53: 4048-52.
20. Kondoh N, Schweinfest CW, Henderson KW, Papas TS. Differential expression of S19 ribosomal protein, laminin-binding protein, and human lymphocyte antigen class I messenger RNAs associated with colon carcinoma progression and differentiation. Cancer Res 1992: 52: 791-6.
21. Vaarala MH, Porvari KS, Kyllönen AP, Mustonen MVJ, Lukkarinen O, Vihko FT. Several genes encoding ribosomal protein are overexpressed in prostate-cancer cell lines, confirmation of L7a and L37 over-expression in prostate-cancer tissue samples. Int J Cancer 1998: 78: 27-32.
22. Wang Q, Yang C, Zhou J, Wang X, Wu M, Liu Z. Cloning and characterization of full-length human ribosomal protein L15 cDNA which was overexpressed in esophageal cancer. Gene 2001: 263: 205-9.
23. Heller DL, Gianola KM, Leinwand LA. A highly conserved mouse gene with a propensity to form pseudogenes in mammals. Mol Cell Biol 1988: 8: 2797-403.
24. Chiao PJ, Shin DM, Sacks PG, Hong WK, Tainsky MA. Elevated expression of the ribosomal protein S2 gene in human tumors. Mol Carcinogenesis 1992: 5: 219-31.
25. Boon K, Caron HN, van Asperen R et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 2001: 20: 1383-93.
26. Goulder P, Conlon C, McIntyre K, McMichael A. Identification of a novel human leukocyte antigen A26-restricted epitope in a conserved region of Gag. AIDS 1996: 10: 1441-3.
27. Tanigaki N, Fruci D, Chersi A, Falasca G, Tosi R, Butler RH. HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products. Human Immunol 1994: 39: 155-62.
28. Ito M, Shichijo S, Tsuda N et al. Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 2001: 61: 2038-46.
29. Yang D, Nakao M, Shichijo S et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999: 59: 4056-63.
30. Morel S, Lévy F, Burlet-Schiltz O et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000: 12: 107-17.
31. Ikeda H, Lethé B, Lehmann F. et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997: 6: 199-208.